United Therapeutics Corporation
1110 Spring Street
Silver Spring
Maryland
20910
United States
Tel: 301-608-9292
Fax: 301-608-9291
Website: http://www.unither.com/
370 articles with United Therapeutics Corporation
-
United Therapeutics Corporation to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/6/2023
United Therapeutics Corporation will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 33rd Annual Healthcare Conference.
-
United Therapeutics Corporation to Present at the Cowen 43rd Annual Health Care Conference
2/28/2023
United Therapeutics Corporation announced that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43rd Annual Health Care Conference in Boston.
-
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
2/22/2023
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022.
-
United Therapeutics Corporation to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/2/2023
United Therapeutics Corporation announced that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41st annual J.P. Morgan Healthcare Conference in San Francisco.
-
United Therapeutics Corporation Reports Third Quarter 2022 Financial Results
11/2/2022
United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended September 30, 2022.
-
United Therapeutics Corporation to Present at the Credit Suisse 31st Annual Healthcare Conference
11/1/2022
United Therapeutics Corporation announced that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the Credit Suisse 31st Annual Healthcare Conference in Los Angeles.
-
United Therapeutics Announces Top Line Data From the EXPEDITE Study of Remodulin Induction Prior to Orenitram Therapy
10/31/2022
United Therapeutics Corporation announced that a preliminary analysis of the EXPEDITE study in patients suffering from World Health Organization Group 1 pulmonary arterial hypertension demonstrated that 79% of patients in the study achieved an Orenitram extended-release tablet dose of at least 4 mg three times daily, for a 12 mg total daily dose at 16 weeks, after an up to eight week induction treatment period with Remodulin injection.
-
United Therapeutics Corporation to Report Third Quarter 2022 Financial Results Before the Market Opens on Wednesday, November 2, 2022
10/26/2022
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022.
-
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2022 Annual Meeting
10/14/2022
United Therapeutics Corporation announced that three presentations and two posters across its commercial and development portfolio will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians taking place October 16-19, 2022, in Nashville, Tennessee.
-
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis
10/11/2022
United Therapeutics Corporation announced that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis at sites outside the United States and Canada.
-
United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report
9/12/2022
United Therapeutics Corporation, a public benefit corporation, announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance priorities.
-
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
8/24/2022
United Therapeutics Corporation, a public benefit corporation, announced that four posters and one oral presentation will be presented at the European Society of Cardiology Congress 2022, taking place August 26-29, 2022, and the European Respiratory Society International Congress 2022, taking place September 4-6, 2022.
-
United Therapeutics Corporation Reports Second Quarter 2022 Financial Results
8/3/2022
United Therapeutics Corporation, a public benefit corporation, announced its financial results for the quarter ended June 30, 2022.
-
United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022
7/27/2022
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.
-
United Therapeutics Provides an Update on Its Organ Printing Programs
6/6/2022
United Therapeutics Corporation, a public benefit corporation, announced that in partnership with 3D Systems Corporation it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated it at the LIFE ITSELF Conference that occurred May 31 to June 3, 2022 in San Diego.
-
United Therapeutics Corporation to Present at the Jefferies Healthcare Conference
6/3/2022
United Therapeutics Corporation announced that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Jefferies Healthcare Conference in New York City.
-
Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
United Therapeutics Announces FDA Approval of Tyvaso DPI™
5/24/2022
United Therapeutics Corporation, a public benefit corporation, announced that the U.S. Food and Drug Administration has approved Tyvaso DPI™ inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.
-
MannKind’s Technosphere® Inhalation Platform Utilized in FDA-Approved Tyvaso DPI™
5/24/2022
MannKind Corporation celebrated that the U.S. Food and Drug Administration has approved United Therapeutics’ Tyvaso DPI™ inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
New research indicates the heart that David Bennet received was infected with porcine cytomegalovirus, a virus that can cause respiratory and pregnancy complications in pigs.